LaunchLab Partners Welcomes Veteran Healthcare Leader Georgette Pascale as Chief Strategic Advisor
FOOTHILL RANCH, CA — May 18, 2026 — LaunchLab Partners, Inc., a healthcare marketing and commercialization agency that partners with early-stage to growth-stage companies to build visibility, accelerate growth, and strengthen market impact, today announced that veteran communications strategist, entrepreneur, and business leader Georgette Pascale has joined as Chief Strategic Advisor. In her new role, Pascale will work closely with LaunchLab Partners’ leadership team and clients across strategic development, communications, partnerships, and public […]
Sydnexis to Present New Data from Phase 3 STAR Trial of SYD-101 at ARVO 2026 Annual Meeting
DEL MAR, Calif., May 1, 2026 – Sydnexis, Inc., a biopharmaceutical company focused on developing a novel low-dose atropine formulation to treat pediatric progressive myopia (PPM), today announced it will present new data related to a prespecified subgroup analysis in children with fast-progressing myopia from the Phase 3 STAR trial of SYD-101 at the Association for Research in Vision and Ophthalmology (ARVO) annual meeting taking place May 3-7, 2026 in Denver, Colorado. Presentation Details […]
Complex Industry, Same Truth: Why Visibility Still Wins in Healthcare Marketing
Written by Rhonda Grandy, Director of Digital Experience & Growth Marketing at LaunchLab Partners One year ago, I stepped into healthcare marketing when I joined LaunchLab Partners as Director of Digital Experience and Growth Marketing. I expected complexity. I expected regulation. I expected longer timelines and more layers of approval. All of that proved true. What I didn’t expect was how much the […]
Atia Vision Announces Durable 36-Month Results from First-in-Human Study of their Dynamic Shape-Changing OmniVu Intraocular Lens System
CAMPBELL, Calif.–(BUSINESS WIRE)–Atia Vision, Inc., a Shifamed portfolio company, today announced positive 36-month results from its first-in-human (FIH) clinical study of the Atia Vision™ OmniVu Lens System, a modular shape-changing intraocular lens (IOL) designed to restore a continuous, dynamic range of vision following cataract surgery. The data was presented by William F. Wiley, M.D., Medical […]
Aurion Biotech Doses First Patients in ASTRA Phase 3 Study, Evaluating AURN001 in Patients with Corneal Edema Secondary to Corneal Endothelial Dysfunction
Seattle, WA; Cambridge, MA; Tokyo, Japan –April 7, 2026 – Aurion Biotech, Inc. (“Aurion Biotech”), a commercial-stage regenerative cell therapy company dedicated to restoring vision and working toward a future where blindness is eliminated, today announced that the first patients have been dosed in the U.S. ASTRA Phase 3 pivotal study of AURN001, a single-administration regenerative cell therapy for corneal edema secondary to corneal endothelial dysfunction. AURN001 has […]
Amaros Launches Interventional Glaucoma Network to Advance Evidence in Interventional Glaucoma
Company also appoints Mark Packer, MD, as Chief Medical Officer and Jai Parekh, MD, as Chief Strategy Officer ATHERTON, Calif.–(BUSINESS WIRE)–Amaros, Inc. (www.amaros.ai), a leader in ophthalmic precision intelligence and the developer of the AI-powered AmarosEngine™ platform, today announced the launch of its Interventional Glaucoma Network (IGN), a clinician-led initiative designed to generate high-quality clinical […]
Five Reasons Market Research Should Come Before Messaging
Written by Yari Mitchell, Co-Founder and Co-CEO of LaunchLab Partners Messaging without research is just guesswork with confidence. In healthcare and medtech, it is tempting to jump straight into messaging. Teams want to define their value proposition, build a brand narrative, and start creating content that drives awareness. But without a clear understanding of the […]
Sydnexis Announces New Data from Phase 3 STAR Trial of SYD-101 Presented at 2026 AAPOS Annual Meeting
DEL MAR, Calif., March 23, 2026 – Sydnexis, Inc., a biopharmaceutical company focused on developing a novel low-dose atropine formulation to treat pediatric progressive myopia (PPM), today announced new data from comprehensive subgroup analyses from the Phase 3 Study of Atropine for the Reduction of Myopia Progression (STAR) trial of SYD-101. The data were presented during an oral session at the 51st Annual Meeting of the […]
Is PR Still a ‘Thing’? Without a Doubt.
Written by Georgette “G” Pascale – Founder of G. and Friend of LaunchLab Partners Public relations is defined as “the state of the relationship between the public and a company/ organization/ other person”. Launch Lab Partners believes that trust, credibility, and visibility are the crucial factors that make PR indispensable. Most people talk about social […]
Aurion Biotech Appoints World Renowned Cornea Surgeon Marjan Farid, M.D.,to Chair Medical Advisory Board
Seattle, WA; Cambridge, MA; Tokyo, Japan – March 11, 2026 – Aurion Biotech, Inc. (“Aurion”), a commercial-stage regenerative cell therapy company dedicated to restoring vision and working toward a future where blindness is eliminated, today announced the appointment of Dr. Marjan Farid of the Gavin Herbert Eye Institute at the University of California-Irvine (UCI) as Chair of […]
